Julie Dodds

IBCL-416: Treatment Preferences of Patients, Caregivers, and Physicians in Follicular Lymphoma (FL): A Global Discrete-Choice Experiment (DCE) Study

Mitchell R. Smith, Mei Xue, Erlene Seymour, Yan Meng et autres

py, gb, us (code pays fourni par la source)

POSTER: IBCL-416 Treatment Preferences of Patients, Caregivers, and Physicians in Follicular Lymphoma (FL): A Global Discrete-Choice Experiment (DCE) Study

Mitchell R. Smith, Mei Xue, Erlene Seymour, Yan Meng et autres

Predicting pain reduction following laparoscopic surgery for endometriosis: a retrospective cohort study using UK national and research databases

Connor Mustard, Kym I E Snell, Kim May Lee, Cleo Pike et autres

OBJECTIVE: To develop and validate models to predict which endometriosis patients are likely to experience pain reduction following therapeutic laparoscopy using intraoperative findings and patient characteristics. DESIGN: A retrospective secondary data analysis with patient workshops. SETTING: Analysis of a UK nationwide, specialist …

ca, gb (code pays fourni par la source)

577 | TREATMENT PREFERENCES OF PATIENTS, CAREGIVERS, AND PHYSICIANS IN FOLLICULAR LYMPHOMA: A GLOBAL DISCRETE‐CHOICE EXPERIMENT STUDY

Mitchell R. Smith, Meilan Xue, Erlene Seymour, Yan Meng et autres

treatment duration and costs) when selecting the appropriate BsAb SC therapies for patients with 3Lþ FL.

gb, us, ca (code pays fourni par la source)

Treatment preferences of patients, caregivers, and physicians in follicular lymphoma (FL): A global discrete-choice experiment (DCE) study.

Mitchell R. Smith, Mei Xue, Erlene Seymour, Yan Meng et autres

11109 Background: While recent FL therapy advances offer various treatment options, data are limited on FL treatment preferences in the shared decision-making process. A comprehensive survey with a DCE design was conducted to assess preferences of patients, caregivers, and physicians for different …

us, gb (code pays fourni par la source)

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Jaffar Abbas et autres

Background: Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not receiving ventilatory support (the combination of non-invasive …

Clinical effectiveness and safety of time-lapse imaging systems for embryo incubation and selection in in-vitro fertilisation treatment (TILT): a multicentre, three-parallel-group, double-blind, randomised controlled trial

Priya Bhide, David Yiu Leung Chan, Doris Lanz, Odai Alqawasmeh et autres

BACKGROUND: Time-lapse imaging systems for embryo incubation and selection might improve outcomes of in-vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) treatment due to undisturbed embryo culture conditions, improved embryo selection, or both. However, the benefit remains uncertain. We aimed to evaluate …

gb, hk, es (code pays fourni par la source)

Metformin in the prevention of type 2 diabetes after gestational diabetes in postnatal women (OMAhA): a UK multicentre randomised, placebo-controlled, double-blind feasibility trial with nested qualitative study

Angeliki Bolou, Zoe Drymoussi, Doris Lanz, Chiamaka Esther Amaefule et autres

OBJECTIVE: To determine the feasibility of a definitive trial of metformin to prevent type 2 diabetes in the postnatal period in women with gestational diabetes. DESIGN: A multicentre, placebo-controlled, double-blind randomised feasibility trial with qualitative evaluation. SETTING: Three inner-city UK National Health …

gb, es (code pays fourni par la source)

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Jonathan R. Abbas et autres

BACKGROUND: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19. METHODS: In the randomised, controlled, …

Architecture and Early Construction of a Multi-Modal Oncology Registry for Follicular Lymphoma

Mitchell R. Smith, Julie Dodds, Hetal Shah, Zoe Drymoussi et autres

Background: Follicular Lymphoma (FL) is the most common indolent lymphoma. While firm data are lacking, global prevalence estimates are >1 million. FL is clinically heterogeneous. Though initial therapy varies, FL responds in most patients, but is not cured. With multiple relapses after …

us (code pays fourni par la source)

Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study

Chiamaka Esther Amaefule, Zoe Drymoussi, Francisco Jose Gonzalez Carreras, María del Carmen Pardo et autres

OBJECTIVES: To determine the feasibility and acceptability of conducting a randomised trial on the effects of myo-inositol in preventing gestational diabetes in high-risk pregnant women. DESIGN: A multicentre, double-blind, placebo-controlled, pilot randomised trial with nested qualitative evaluation. SETTING: weeks' gestation with risk …

gb, es (code pays fourni par la source)

Rapid intrapartum test for maternal group B streptococcal colonisation and its effect on antibiotic use in labouring women with risk factors for early-onset neonatal infection (GBS2): cluster randomised trial with nested test accuracy study

Jane Daniels, Emily Dixon, Alicia Gill, Jonathan Bishop et autres

BACKGROUND: Mother-to-baby transmission of group B Streptococcus (GBS) is the main cause of early-onset infection. We evaluated whether, in women with clinical risk factors for early neonatal infection, the use of point-of-care rapid intrapartum test to detect maternal GBS colonisation reduces maternal …

gb, es (code pays fourni par la source)